“
“Background Invasive fungal infections (IFIs) are a major cause of mortality among allogeneic hematopoietic A 769662 stem cell transplantation (allo-HSCT) patients. Thanks to the widespread

use of secondary antifungal prophylaxis (SAP), a history of IFI is not an absolute contraindication to allo-HSCT. However, IFI recurrence remains a risk factor for transplant-related mortality. Methods To evaluate the risk factors for IFI recurrence in allo-HSCT patients receiving SAP, we performed a retrospective analysis of 90 individuals treated at our hospital. SAP antifungal agents included fluconazole (n=28), voriconazole (n=25), itraconazole (n=23), caspofungin (n=7), and micafungin (n=7). Results By day +100, recurrent IFI had occurred in 23 (25.5%) patients. Silmitasertib mouse Our multivariate analysis identified 4 factors significantly associated with a risk of IFI recurrence within 100days of allo-HSCT: duration of neutropenia >18days, presence of severe acute graft-versus-host disease (aGVHD), <70-day interval between previous infection and transplantation, and use of a narrow-spectrum SAP agent (P=0.008, 0.010, 0.041, and 0.001, respectively).

Of the 87 patients who remained in the study for the duration of the follow-up period (median length: 551days), 26 (29.9%) died; only 7 (8.0%) of these deaths resulted from a severe fungal infection. Conclusion These results suggest that transplantation outcome can be improved by adequate antifungal treatment before transplantation, better prevention of, and therapy for, severe aGVHD, use of granulocyte colony-stimulating factor to reduce the duration of neutropenia, and use of broad-spectrum prophylaxis agents.”
“Objective. Painful bladder syndrome/interstitial cystitis (PBS/IC) is an inflammatory bladder disease of unknown origin. Symptoms of PBS/IC Natural Product Library screening compromise patients’ quality of life (QoL).

This study evaluated a health-related quality of life (HRQoL) questionnaire in PBS/IC. Material and methods. 151 patients with PBS/IC filled in the HRQoL questionnaire before and after the treatment. Of these, 87 patients participated in a 3-month randomized study testing intravesical dimethyl sulfoxide (DMSO) and bacille Calmette-Guerin (BCG) and 64 patients took part in a 6-month randomized study evaluating oral cyclosporine A (CyA) and pentosan polysulfate sodium (PPS). The changes in HRQoL questionnaire were evaluated with respect to the changes in global response assessment (GRA). Results. The results of the HRQoL questionnaire reflected well the post-treatment GRA. Patients responding to their treatment had improved QoL. CyA treatment had more impact on emotional well-being, social functioning, activity limitation days, pain and physical capacity than PPS treatment (p0.05). More patients responded to DMSO than BCG treatment according to GRA (p0.